Last reviewed · How we verify
IGNX001
At a glance
| Generic name | IGNX001 |
|---|---|
| Sponsor | IgGenix Australia Pty Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IGNX001 CI brief — competitive landscape report
- IGNX001 updates RSS · CI watch RSS
- IgGenix Australia Pty Ltd portfolio CI